
Upstream Bio, Inc.
UPBHealthcare|Biotechnology|US
$3.23
+0.02 (+0.62%)
Tangible Book / Share
$4.97
Cash / Share
$4.79
Next Earnings Report
Mar 17, 2027
EPS est. -$0.73 · Revenue est. $524.1K
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest Mar 26, 2026 (424B5). Possible dilution.
Upcoming Data Readouts (2)
Sep 2027
Est. completion
P2Severe Asthma
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479n=396
Oct 2027
Est. completion
P2Chronic Obstructive Pulmonary Disease
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
NCT06981078n=666
Recent Press Releases
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
Sep 8, 2026 · GlobeNewsWire
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
Sep 1, 2026 · GlobeNewsWire
SEC Filings (44)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 6, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Oct 29, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Sep 1, 2026 | 8-K | Material event | DocumentIndex |
| Aug 12, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 11, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Aug 11, 2026 | 8-K | Material event | DocumentIndex |
| Jul 30, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Jun 10, 2026 | 8-K | Material event | DocumentIndex |
| May 15, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 13, 2026 | 10-Q | Quarterly report | DocumentIndex |
| May 13, 2026 | 8-K | Material event | DocumentIndex |
| Apr 16, 2026 | ARS | Annual report to holders | DocumentIndex |
| Apr 16, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 16, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Mar 26, 2026 | 8-K | Material event | DocumentIndex |
| Mar 26, 2026 | 424B5 | Offering prospectus | DocumentIndex |
| Mar 26, 2026 | S-8 | Employee stock plan | DocumentIndex |
| Mar 26, 2026 | 10-K | Annual report | DocumentIndex |
| Mar 26, 2026 | 8-K | Material event | DocumentIndex |
| Feb 11, 2026 | 8-K | Material event | DocumentIndex |
| Feb 11, 2026 | 8-K | Material event | DocumentIndex |
| Nov 14, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Nov 14, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Nov 5, 2025 | S-3ASR | Shelf registration | DocumentIndex |
| Nov 5, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Nov 5, 2025 | 8-K | Material event | DocumentIndex |
| Oct 24, 2025 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Sep 2, 2025 | 8-K | Material event | DocumentIndex |
| Aug 6, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 6, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Aug 6, 2025 | 8-K | Material event | DocumentIndex |
| Jun 12, 2025 | 8-K | Material event | DocumentIndex |
| May 6, 2025 | 10-Q | Quarterly report | DocumentIndex |
| May 6, 2025 | 8-K | Material event | DocumentIndex |
| Apr 17, 2025 | ARS | Annual report to holders | DocumentIndex |
| Apr 17, 2025 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 17, 2025 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Mar 12, 2025 | S-8 | Employee stock plan | DocumentIndex |
| Mar 12, 2025 | 10-K | Annual report | DocumentIndex |
| Mar 12, 2025 | 8-K | Material event | DocumentIndex |